Chemours (CC) Common Equity (2014 - 2026)

Chemours' Common Equity history runs 13 years deep, the most recent figure standing at $215.0 million for Q1 2026.

• In Q1 2026, Common Equity fell 62.08% year-over-year to $215.0 million; the TTM figure through Mar 2026 stood at $215.0 million (down 62.08% YoY), while the FY2025 annual figure was $250.0 million, down 56.29% from the prior year.
• Common Equity was $215.0 million for Q1 2026 at Chemours, down from $250.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.8 billion in Q2 2024 to a low of -$15.0 million in Q1 2024.
• Historically, Common Equity has averaged $818.5 million across 5 years, with a median of $749.0 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Common Equity sank 101.22% in 2024, then jumped 3880.0% in 2025.
• A 5-year view of Common Equity shows it stood at $1.1 billion in 2022, then sank by 34.63% to $723.0 million in 2023, then slipped by 20.89% to $572.0 million in 2024, then sank by 56.29% to $250.0 million in 2025, then slipped by 14.0% to $215.0 million in 2026.
• The last three Common Equity figures came in at $215.0 million (Q1 2026), $250.0 million (Q4 2025), and $276.0 million (Q3 2025), per Business Quant data.